Collisions YYC

In this episode, you’ll learn about the pharmaceutical application of cannabis. With the legalization of cannabis in Canada, R&D and commercialization in medical cannabis are poised to reap rewards. Stephen Van Deventer, Chairman and CEO of Astern Cannabis Inc. and PreveCeutical Medical Inc., discusses how they fingerprint cannabis cannabinoids, terpenes, and flavonoids to determine their medical applications. Stephen discusses PreveCeutical’s expansion into Australia, the Canadian government’s reaction to their findings, and how his company is approaching commercialization in a different way, as well as how investors are responding.

Show Notes

Investors investing in pharmaceuticals can be nervous about the lengthy process from R&D to commercialization and the regulatory approval processes. PreveCeuticals has diversified its research into four unique applications, which include three that have already been proven. Stephen took a bold approach of researching multiple solutions at once - something that can make investors feel a bit nervous. Stephen wants to develop treatments for major global medical issues like the opioid epidemic in Canada, and he knows exploring multiple projects at once is a faster way to do just that. Learn more about how to commercialize and invest in pharmaceuticals, particularly ‘fringe’ medicines such as cannabis.

What is Collisions YYC?

Tired of the same old news cycle? Get informed on what’s happening in businesses in Calgary, Alberta and beyond with Collisions YYC.

Tyler Chisholm hosts Alberta’s best and brightest minds who are shaping the very landscape of our province with their work in fields like Technology, FinTech, Energy, Healthcare, Education, AI, and more. Tyler’s inherent curiosity and exploratory style fuel candid conversations with the people who are driving change in our city, our province and the world.

Connect with us on social media:
https://www.instagram.com/collisionsyyc